Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Clinical trial NCT04807166 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04807166
Sponsor: Wenjun Cheng
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Neoplasms Fallopian Tube Neoplasms Neoplasms by Site Genital Neoplasms, Female Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Carcinoma, Ovarian Epithelial Ovarian Diseases Genital Diseases, Female Endocrine System Diseases Carcinoma Anlotinib

Start date: 2021-08-24
Primary completion: 2025-09-30
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.